EY Releases M&A Report for 2018
EY launched its M&A Firepower report, showing that life sciences mergers and acquisitions (M&A) activity in 2018 totaled $198 billion USD. According to the report, life sciences companies focused on building therapeutic scale and optimizing their portfolios, and the 2018 market conditions-especially high valuations for target acquisitions-drove dealmaking away from megamergers toward bolt-on acquisitions and divestitures.
Additionally, the uncertain return on investment and the rapid pace of technology change mean life sciences companies will likely prioritize digital alliances in favor of M&A in 2019.
Key findings highlighted in this year’s M&A Firepower report include:
- Total M&A deal value driven by bolt-ons and divestitures, not megamergers
- Firepower remains robust but is not being deployed
- Focused companies outperform less focused counterparts
- Market fragmentation likely to drive additional deals
The report identifies a number of key industry trends likely to drive M&A in 2019 and beyond:
- Continued emphasis on portfolio optimization
- Divestitures will increasingly be used to unlock value
- Digital alliances should be a priority too
Read the full report here.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Talphera Cuts NEPHRO CRRT Study Size, Secures $14.8 Million Private Placement
April 1st 2025The trial size adjustment, along with protocol modifications and the addition of higher-enrollment sites, is expected to facilitate completion of the NEPHRO CRRT study of Niyad in patients undergoing renal replacement therapy by the end of 2025.
